

We are located in Paris
At MedInsights, we aim to revolutionize metabolic disease treatment. Our core strength lies in Nexus-Rx, an advanced drug identification and optimization engine. By integrating proprietary explainable AI models with deep graph learning technologies, we identify unknown and unforeseen relationships between disease-targets-drugs. These predicted candidates are rigorously validated through preclinical and clinical collaborations, to ultimately deliver transformative therapies to patients.
​
​
We are a AI driven biotech company with a vision to transform the treatment landscape for metabo-inflammatory diseases. Our commitment to innovation and patient-centricity fuels our drive to deliver effective, targeted therapies.
​
Introducing Our Fully-Integrated Drug Discovery Framework NEXUS-Rx
-
Unified data umbrella: Seamlessly generate insights from over 25+ sources, including clinical trials, publications, omics datasets, patents, anonymized patient datasets (proprietary) and other specialized databases (internal and external).
-
Navigating the Disease Landscape: Generate comprehensive network models that visualize disease progression and drug interactions at the molecular level.
-
Exploring Hidden Connections: Find correspondence between networks to to identify promising drug-disease matches that might have been missed.
-
Expansion of Treatment Options: Uncover novel uses for existing medications based on their interaction with disease pathways and pharmacological actions.
-
Accelerate Drug Development: Pinpoint promising drug leads with high potential for further development.
-
Optimize Clinical Trials: Clinical endpoint mapping and adverse events mapping facilitates identification of potential biomarkers that can streamline drug development by analyzing previous treatment response in patients.
How NEXUS-Rx works?

OUR CLIENT PORTFOLIO






















MEMBERSHIPS
MedInsights is a part of REPO4EU and Paris Biotech Santé

